Elanco Animal Health Incorporated (NYSE:ELAN) Receives $15.00 Consensus Price Target from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned a consensus rating of “Hold” from the seven research firms that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $15.17.

ELAN has been the subject of a number of analyst reports. Barclays reduced their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. UBS Group reduced their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus upped their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a report on Monday. Finally, Piper Sandler reduced their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th.

Insider Activity

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the acquisition, the director now directly owns 101,459 shares in the company, valued at $1,105,903.10. This represents a 10.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.89% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its stake in Elanco Animal Health by 28.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock valued at $124,000 after buying an additional 2,264 shares during the period. DDD Partners LLC bought a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $5,974,000. Dimensional Fund Advisors LP lifted its holdings in Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock worth $216,774,000 after purchasing an additional 1,074,274 shares during the last quarter. Franklin Resources Inc. raised its holdings in Elanco Animal Health by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock valued at $5,349,000 after acquiring an additional 45,795 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after acquiring an additional 2,059 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Up 2.5%

Elanco Animal Health stock opened at $13.24 on Thursday. The company has a market capitalization of $6.58 billion, a P/E ratio of 33.10, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average price of $10.16 and a 200-day moving average price of $11.44. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 EPS. As a group, equities analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.